Manny Pacquiao & LTNC Takeover Industries Enter into Joint Venture Distribution Agreement to Manufacture in Philippines and Distribute in Asia
May 12, 2021 13:00 ET | Source: Labor Smart, Inc Labor Smart, Inc Powder Springs, Georgia, UNITED STATES
ATLANTA, May 12, 2021 (GLOBE NEWSWIRE) Labor SMART, Inc. (LTNC) (the “Company”), announced that its recently acquired subsidiary, Takeover Industries Inc., has entered into a Joint Venture Agreement with Boxing Legend and Politician Manny Pacquiao to manufacture NXT LVL products in the Republic of the Philippines for distribution throughout Asia.
This Joint Venture combines Team Takeover’s unique and extensive knowledge and experience in the health and beverage industry with Manny Pacquiao’s network of business associates and resources overseas. The company believes this partnership will introduce manufacturing capabilities and support sales and distribution of NXT LVL
Single-Use Bioprocessing Market Grows $6 7 Billion Projects industrialinfo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from industrialinfo.com Daily Mail and Mail on Sunday newspapers.
Pharma Projects Strive to Meet Growing Veterinary Demand in South America
Industry Segment: Pharmaceutical & Biotech | Word Count: 152 Words
Attachment: A
CORDOBA, ARGENTINA April 8, 2021 Researched by Industrial Info Resources (Sugar Land, Texas) Pharmaceutical products for the veterinary industry are big business in South America. According to Market Data Forecast, the veterinary healthcare market in Latin America was worth $3.46 billion in 2020 and is expected to grow to $5.11 billion by 2025.
Industrial Info s Global Market Intelligence (GMI) Database includes information on 31 plants that manufacture veterinary pharmaceutical products in South America and has identified 44 related projects, worth $251.87 million.
Ethypharm ready to bring to patients world-leading digital therapies for depression and addiction
Ethypharm announces today that it has acquired exclusive rights for two CE-marked digital therapies, deprexis and vorvida
, developed by GAIA AG (GAIA), a global leader in digital therapeutics. With these innovative clinically-proven digital therapies, Ethypharm strengthens its product offering to support patients and healthcare providers in its core area of the Central Nervous System (CNS) where there are significant unmet needs.
30 million European individuals suffer from depression. The burden of mental disorders is growing, with significant impacts on health and major social and economic consequences. The ongoing COVID-19 pandemic is leading to an increase in cases of depression and alcohol use disorders (AUD). In parallel, to address the pandemic, digital health technologies have been adopted at a fast pace to help maintain an appropriate care of patients.